| ABC294640 |
915385-81-8 |
ABC294640 is a selective inhibitor of sphingosine kinase-2(SK2).... |
| ABC294640 |
915385-81-8 |
ABC294640 is a selective inhibitor of sphingosine kinase-2(SK2).... |
| ABC294640 |
915385-81-8 |
ABC294640 is a selective inhibitor of sphingosine kinase-2(SK2).... |
| ABR215062 |
248281-84-7 |
.... |
| ABR215062 |
248281-84-7 |
.... |
| AC220 |
950769-58-1 |
AC220 is a unique, potent and selective inhibitor of fms-like tyrosine kinase (FLT3) with IC50 values of 1.1 and 4.2 nM for internal tandem duplications mutation FLT3 (FLT3-ITD) and wild type FLT3 (FLT3-WT) autophosphorylation, respectively.... |
| AC220 |
950769-58-1 |
AC220 is a unique, potent and selective inhibitor of fms-like tyrosine kinase (FLT3) with IC50 values of 1.1 and 4.2 nM for internal tandem duplications mutation FLT3 (FLT3-ITD) and wild type FLT3 (FLT3-WT) autophosphorylation, respectively.... |
| AC220 |
950769-58-1 |
AC220 is a unique, potent and selective inhibitor of fms-like tyrosine kinase (FLT3) with IC50 values of 1.1 and 4.2 nM for internal tandem duplications mutation FLT3 (FLT3-ITD) and wild type FLT3 (FLT3-WT) autophosphorylation, respectively.... |
| AC220 |
950769-58-1 |
AC220 is a unique, potent and selective inhibitor of fms-like tyrosine kinase (FLT3) with IC50 values of 1.1 and 4.2 nM for internal tandem duplications mutation FLT3 (FLT3-ITD) and wild type FLT3 (FLT3-WT) autophosphorylation, respectively.... |
| ACT064992 |
441798-33-0 |
.... |
| AEE788 |
497839-62-0 |
AEE788 is a novel multitargeted inhibitor of EGFR, ErbB2, KDR, and Flt-1 with IC50 values of 2, 6, 77 and 59 nM, respectively.... |
| AEE788 |
497839-62-0 |
AEE788 is a novel multitargeted inhibitor of EGFR, ErbB2, KDR, and Flt-1 with IC50 values of 2, 6, 77 and 59 nM, respectively.... |
| AEE788 |
497839-62-0 |
AEE788 is a novel multitargeted inhibitor of EGFR, ErbB2, KDR, and Flt-1 with IC50 values of 2, 6, 77 and 59 nM, respectively.... |
| AEE788 |
497839-62-0 |
AEE788 is a novel multitargeted inhibitor of EGFR, ErbB2, KDR, and Flt-1 with IC50 values of 2, 6, 77 and 59 nM, respectively.... |
| Afatinib |
850140-72-6 |
.... |
| Afatinib |
850140-72-6 |
.... |
| Afatinib |
850140-72-6 |
.... |
| Afatinib |
850140-72-6 |
.... |
| AG-1024 |
65678-07-1 |
AG1024 is an IGF-1R inhibitor.... |
| AG-1478 |
153436-53-4 |
AG-1478 is an inhibitor of the EGFR tyrosine kinase.... |
| AG-1478 |
153436-53-4 |
AG-1478 is an inhibitor of the EGFR tyrosine kinase.... |
| AG-1478 |
153436-53-4 |
AG-1478 is an inhibitor of the EGFR tyrosine kinase.... |
| AG-1478 |
153436-53-4 |
AG-1478 is an inhibitor of the EGFR tyrosine kinase.... |
| AG-490 |
133550-30-8 |
AG-490 is a specific janus kinase 2 (JAK2) inhibitor.... |
| AG-490 |
133550-30-8 |
AG-490 is a specific janus kinase 2 (JAK2) inhibitor.... |
| AG879 |
148741-30-4 |
AG 879 is widely used specific Tyr kinase inhibitor for ErbB2 and FLK-1 (a VEGF receptor).... |
| AG879 |
148741-30-4 |
AG 879 is widely used specific Tyr kinase inhibitor for ErbB2 and FLK-1 (a VEGF receptor).... |
| AG879 |
148741-30-4 |
AG 879 is widely used specific Tyr kinase inhibitor for ErbB2 and FLK-1 (a VEGF receptor).... |
| AKT Kinase Inhibitor |
842148-40-7 |
.... |
| AMG-073 |
364782-34-3 |
.... |
| AMG-073 |
364782-34-3 |
.... |
| AMG-208 |
1002304-34-8 |
AMG 208 is a potent and selective inhibitor of kinase c-Met.... |
| AMG-208 |
1002304-34-8 |
AMG 208 is a potent and selective inhibitor of kinase c-Met.... |
| AMG-208 |
1002304-34-8 |
AMG 208 is a potent and selective inhibitor of kinase c-Met.... |
| AMG-208 |
1002304-34-8 |
AMG 208 is a potent and selective inhibitor of kinase c-Met.... |
| AMG-208 |
1002304-34-8 |
AMG 208 is a potent and selective inhibitor of kinase c-Met.... |
| AMG-208 |
1002304-34-8 |
AMG 208 is a potent and selective inhibitor of kinase c-Met.... |
| AMG-208 |
1002304-34-8 |
AMG 208 is a potent and selective inhibitor of kinase c-Met.... |
| AMG458 |
913376-83-7 |
AMG458 is a novel selective c-Met inhibitor.... |
| AMG458 |
913376-83-7 |
AMG458 is a novel selective c-Met inhibitor.... |
| AMG458 |
913376-83-7 |
AMG458 is a novel selective c-Met inhibitor.... |
| AMG458 |
913376-83-7 |
AMG458 is a novel selective c-Met inhibitor.... |
| Amuvatinib |
850879-09-3 |
Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively [1].... |
| Amuvatinib |
850879-09-3 |
Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively [1].... |
| Amuvatinib |
850879-09-3 |
Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively [1].... |
| Amuvatinib |
850879-09-3 |
Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively [1].... |
| AP26113 |
1197958-12-5 |
.... |
| Apatinib |
811803-05-1 |
Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR) with IC50 of 1nM [1].... |
| Apatinib |
811803-05-1 |
Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR) with IC50 of 1nM [1].... |
| Apatinib |
811803-05-1 |
Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR) with IC50 of 1nM [1].... |
| Apixaban |
503612-47-3 |
.... |
| Apixaban |
503612-47-3 |
.... |
| ARQ-197 |
1000873-98-2 |
ARQ-197 is the first non-ATP-competitive and selective c-Met receptor inhibitor.... |
| ARQ-197 |
1000873-98-2 |
ARQ-197 is the first non-ATP-competitive and selective c-Met receptor inhibitor.... |
| ARQ-197 |
1000873-98-2 |
ARQ-197 is the first non-ATP-competitive and selective c-Met receptor inhibitor.... |
| ARQ-197 |
1000873-98-2 |
ARQ-197 is the first non-ATP-competitive and selective c-Met receptor inhibitor.... |
| ARQ197 |
905854-02-6 |
Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM.... |
| ARQ197 |
905854-02-6 |
Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM.... |
| AS1892802 |
928320-12-1 |
AS1892802 is a novel and highly selective Rho kinase (ROCK) inhibitor.... |
| AS1892802 |
928320-12-1 |
AS1892802 is a novel and highly selective Rho kinase (ROCK) inhibitor.... |
| AT13148 |
1056901-62-2 |
AT13148 is an oral ATP-competitive multi-AGC kinase inhibitor.... |
| AT13387 |
912999-49-6 |
AT13387 is a potent and selective inhibitor of Hsp90.... |
| AT13387 |
912999-49-6 |
AT13387 is a potent and selective inhibitor of Hsp90.... |
| AT13387 |
912999-49-6 |
AT13387 is a potent and selective inhibitor of Hsp90.... |
| AT13387 |
912999-49-6 |
AT13387 is a potent and selective inhibitor of Hsp90.... |
| AT7867 |
857531-00-1 |
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase.... |
| AT7867 |
857531-00-1 |
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase.... |
| AT7867 |
857531-00-1 |
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase.... |
| AV-412 |
451492-95-8 |
AV-412 is a potent dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases, including the mutant EGFRL858R,T790M.... |
| AVL-292 |
1202757-89-8 |
AVL-292 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| AVL-292 |
1202757-89-8 |
AVL-292 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| AVL-292 |
1202757-89-8 |
AVL-292 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| AVL-292 |
1202757-89-8 |
AVL-292 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| AVL-292 |
1202757-89-8 |
AVL-292 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| Axitinib |
319460-85-0 |
Axitinib is a potent and selective inhibitor of VEGF receptor tyrosine kinase (RTK) 1, 2, and 3.... |
| Axitinib |
319460-85-0 |
Axitinib is a potent and selective inhibitor of VEGF receptor tyrosine kinase (RTK) 1, 2, and 3.... |
| AZD1152-HQPA |
722544-51-6 |
AZD1152-HQPA is a specific inhibitor of the enzymatic activity of Aurora kinase.... |
| AZD1480 |
935666-88-9 |
AZD1480 is a potent ATP competitive inhibitor of JAK2 kinase, with an inhibition constant (Ki) of 0.26 nM.... |
| AZD1480 |
935666-88-9 |
AZD1480 is a potent ATP competitive inhibitor of JAK2 kinase, with an inhibition constant (Ki) of 0.26 nM.... |
| AZD1480 |
935666-88-9 |
AZD1480 is a potent ATP competitive inhibitor of JAK2 kinase, with an inhibition constant (Ki) of 0.26 nM.... |
| AZD1480 |
935666-88-9 |
AZD1480 is a potent ATP competitive inhibitor of JAK2 kinase, with an inhibition constant (Ki) of 0.26 nM.... |
| AZD2858 |
486424-20-8 |
.... |
| AZD3463 |
1356962-20-3 |
.... |
| AZD3463 |
1356962-20-3 |
AZD-3463 inhibits ALK with a Ki value of 0.75 nM.... |
| AZD4547 |
1035270-39-3 |
AZD4547 is a potent selective FGFR inhibitor.... |
| AZD4547 |
1035270-39-3 |
AZD4547 is a potent selective FGFR inhibitor.... |
| AZD4547 |
1035270-39-3 |
AZD4547 is a potent selective FGFR inhibitor.... |
| AZD4547 |
1035270-39-3 |
AZD4547 is a potent selective FGFR inhibitor.... |
| AZD4547 |
1035270-39-3 |
AZD4547 is a potent selective FGFR inhibitor.... |
| AZD8931 |
848942-61-0 |
AZD8931 is a reversible, ATP competitive inhibitor of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor with IC50 of 4, 3 and 4 nM, respectively.... |
| AZD8931 |
848942-61-0 |
AZD8931 is a reversible, ATP competitive inhibitor of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor with IC50 of 4, 3 and 4 nM, respectively.... |
| AZD8931 |
848942-61-0 |
AZD8931 is a reversible, ATP competitive inhibitor of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor with IC50 of 4, 3 and 4 nM, respectively.... |
| AZD8931 |
848942-61-0 |
AZD8931 is a reversible, ATP competitive inhibitor of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor with IC50 of 4, 3 and 4 nM, respectively.... |
| BGJ398 |
872511-34-7 |
BGJ398 is a potent and selective inhibitor of the FGFR family of tyrosine kinase receptors FGFR1, FGFR2, FGFR3, and FGFR4 with IC50s of 0.9, 1.4, 1 and 60 nM, respectively.... |
| BGJ398 |
872511-34-7 |
BGJ398 is a potent and selective inhibitor of the FGFR family of tyrosine kinase receptors FGFR1, FGFR2, FGFR3, and FGFR4 with IC50s of 0.9, 1.4, 1 and 60 nM, respectively.... |
| BGJ398 |
872511-34-7 |
BGJ398 is a potent and selective inhibitor of the FGFR family of tyrosine kinase receptors FGFR1, FGFR2, FGFR3, and FGFR4 with IC50s of 0.9, 1.4, 1 and 60 nM, respectively.... |
| BGJ398 |
872511-34-7 |
BGJ398 is a potent and selective inhibitor of the FGFR family of tyrosine kinase receptors FGFR1, FGFR2, FGFR3, and FGFR4 with IC50s of 0.9, 1.4, 1 and 60 nM, respectively.... |
| BGJ398 |
872511-34-7 |
BGJ398 is a potent and selective inhibitor of the FGFR family of tyrosine kinase receptors FGFR1, FGFR2, FGFR3, and FGFR4 with IC50s of 0.9, 1.4, 1 and 60 nM, respectively.... |
| BIBF1120 |
656247-17-5 |
BIBF1120 is a potent vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR) and fibroblast growth factor receptors (FGFR) kinase inhibitor.... |
| BIBF1120 |
656247-17-5 |
BIBF1120 is a potent vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR) and fibroblast growth factor receptors (FGFR) kinase inhibitor.... |
| BIBF1120 |
656247-17-5 |
BIBF1120 is a potent vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR) and fibroblast growth factor receptors (FGFR) kinase inhibitor.... |
| BIBF1120 |
656247-17-5 |
BIBF1120 is a potent vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR) and fibroblast growth factor receptors (FGFR) kinase inhibitor.... |
| BIBW2992 |
439081-18-2 |
BIBW2992 is an irreversible inhibitor of ErbB family with IC50s of 0.5, 14 and 1 nM for epidermal growth factor receptor (EGFR) (ErbB1/HER1), HER2 and HER4 kinases.... |
| BIBW2992 |
439081-18-2 |
BIBW2992 is an irreversible inhibitor of ErbB family with IC50s of 0.5, 14 and 1 nM for epidermal growth factor receptor (EGFR) (ErbB1/HER1), HER2 and HER4 kinases.... |
| BIBW2992 |
439081-18-2 |
BIBW2992 is an irreversible inhibitor of ErbB family with IC50s of 0.5, 14 and 1 nM for epidermal growth factor receptor (EGFR) (ErbB1/HER1), HER2 and HER4 kinases.... |
| BIBW2992 |
439081-18-2 |
BIBW2992 is an irreversible inhibitor of ErbB family with IC50s of 0.5, 14 and 1 nM for epidermal growth factor receptor (EGFR) (ErbB1/HER1), HER2 and HER4 kinases.... |
| BML-190 |
2854-32-2 |
.... |
| BMN673 |
1207456-01-6 |
.... |
| BMS-536924 |
468740-43-4 |
BMS-536924 is a novel small-molecule inhibitor which prevents activity of the insulin-like growth factor receptor kinase.... |
| BMS-554417 |
468741-42-6 |
BMS-554417 is a inhibitor of IGF1R/IR and inhibits focal adhesion kinase (FAK) activity.... |
| BMS-777607 |
1196681-44-3 |
BMS777607 is a selective and orally efficacious inhibitor of the Met kinase superfamily.... |
| BMS-794833 |
1174046-72-0 |
.... |
| BMS-833923 |
1059734-66-5 |
.... |
| BMS-833923 |
1059734-66-5 |
.... |
| BMS777607 |
1196681-44-3 |
BMS777607 is a selective and orally efficacious inhibitor of the Met kinase superfamily.... |
| BMS777607 |
1196681-44-3 |
BMS777607 is a selective and orally efficacious inhibitor of the Met kinase superfamily.... |
| BMS790052 |
1009119-65-6 |
.... |
| Bosutinib |
380843-75-4 |
Bosutinib is a novel orally active, competitive inhibitor of both Src and Abl tyrosine kinases with IC50 values of 1.2 nM and 1.4 nM, respectively.... |
| Bosutinib |
380843-75-4 |
Bosutinib is a novel orally active, competitive inhibitor of both Src and Abl tyrosine kinases with IC50 values of 1.2 nM and 1.4 nM, respectively.... |
| BPI-2009H |
610798-31-7 |
.... |
| BPR1J-097 |
1327167-19-0 |
BPR1J-097 is a novel fms-like tyrosine 3 (FLT3) kinase inhibitor.... |
| Brivanib (bms-540215) |
649735-46-6 |
Brivanib is a dual FGF/VEGF inhibitor.... |
| Brivanib (bms-540215) |
649735-46-6 |
Brivanib is a dual FGF/VEGF inhibitor.... |
| Brivanib (bms-540215) |
649735-46-6 |
Brivanib is a dual FGF/VEGF inhibitor.... |
| Brivanib (bms-540215) |
649735-46-6 |
Brivanib is a dual FGF/VEGF inhibitor.... |
| BVT 948 |
39674-97-0 |
BVT 948 is a non-competitive of protein tyrosine phosphatases (PTP) with IC50 ranging from 90 nM to 1.7 μM.... |
| BVT 948 |
39674-97-0 |
BVT 948 is a non-competitive of protein tyrosine phosphatases (PTP) with IC50 ranging from 90 nM to 1.7 μM.... |
| C646 |
328968-36-1 |
.... |
| CCT137690 |
1095382-05-0 |
CCT137690 is a potent and selective inhibitor of Aurora kinases.... |
| CCT137690 |
1095382-05-0 |
CCT137690 is a potent and selective inhibitor of Aurora kinases.... |
| Cediranib |
288383-20-0 |
Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.... |
| Cediranib |
288383-20-0 |
Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.... |
| Cediranib |
288383-20-0 |
Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.... |
| Cediranib |
288383-20-0 |
Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.... |
| CEP-32496 |
1188910-76-0 |
CEP-32496 is a potent BRAF inhibitor.... |
| CEP-32496 |
1188910-76-0 |
CEP-32496 is a potent BRAF inhibitor.... |
| |
|
|
| CEP-32496 |
1188910-76-0 |
CEP-32496 is a potent BRAF inhibitor.... |
| CEP-7055 |
402857-58-3 |
CEP-7055 is a fully synthetic orally active pan-VEGF-R kinase inhibitor.... |
| CGS 21680 hydrochloride |
124182-57-6 |
.... |
| CH5424802 |
1256580-46-7 |
CH5424802 is a potent, selective and orally available anaplastic lymphoma kinase (ALK) inhibitor.... |
| CH5424802 |
1256580-46-7 |
CH5424802 is a potent, selective and orally available anaplastic lymphoma kinase (ALK) inhibitor.... |
| CH5424802 |
1256580-46-7 |
CH5424802 is a potent, selective and orally available anaplastic lymphoma kinase (ALK) inhibitor.... |
| CH5424802 |
1256580-46-7 |
CH5424802 is a potent, selective and orally available anaplastic lymphoma kinase (ALK) inhibitor.... |
| CI-1033 (Canertinib) |
267243-28-7 |
CI-1033 is an irreversible Pan-erbB tyrosine kinase inhibitor.... |
| CI-1033 (Canertinib) |
267243-28-7 |
CI-1033 is an irreversible Pan-erbB tyrosine kinase inhibitor.... |
| CI-1033 (Canertinib) |
267243-28-7 |
CI-1033 is an irreversible Pan-erbB tyrosine kinase inhibitor.... |
| CI-1033 (Canertinib) |
267243-28-7 |
CI-1033 is an irreversible Pan-erbB tyrosine kinase inhibitor.... |
| CID16020046 |
834903-43-4 |
CID16020046 is a selective G protein-coupled receptor 55(GPR55) antagonist.... |
| CID16020046 |
834903-43-4 |
CID16020046 is a selective G protein-coupled receptor 55(GPR55) antagonist.... |
| CO-1686 |
1374640-70-6 |
CO-1686 is a potent and mutant-selective EGFR inhibitor.... |
| CP-724714 |
537705-08-1 |
CP-724,714 is a selective inhibitor of epidermal growth factor 2(erbB/2) tyrosine kinase.... |
| CP673451 |
343787-29-1 |
.... |
| CP673451 |
343787-29-1 |
.... |
| CP673451 |
343787-29-1 |
.... |
| CP673451 |
343787-29-1 |
.... |
| Crizotinib(PF-02341066) |
877399-52-5 |
Crizotinib is a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).... |
| Crizotinib(PF-02341066) |
877399-52-5 |
Crizotinib is a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).... |
| Crizotinib(PF-02341066) |
877399-52-5 |
Crizotinib is a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).... |
| CUDC-101 |
1012054-59-9 |
CUDC-101 is a potent HDAC, EGFR and HER2 inhibitor with IC50 values of 4.4, 2.4, and 15.7 nM, respectively.... |
| CUDC-101 |
1012054-59-9 |
CUDC-101 is a potent HDAC, EGFR and HER2 inhibitor with IC50 values of 4.4, 2.4, and 15.7 nM, respectively.... |
| CUDC-101 |
1012054-59-9 |
CUDC-101 is a potent HDAC, EGFR and HER2 inhibitor with IC50 values of 4.4, 2.4, and 15.7 nM, respectively.... |
| CYC116 |
693228-63-6 |
.... |
| CYT387 |
1056634-68-4 |
CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 and 18 nM, respectively.... |
| CYT387 |
1056634-68-4 |
CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 and 18 nM, respectively.... |
| CYT387 |
1056634-68-4 |
CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 and 18 nM, respectively.... |
| Dabrafenib Mesylate |
1195768-06-9 |
Dabrafenib mesylate is a mutant-BRAF kinase inhibitor.... |
| Dabrafenib Mesylate |
1195768-06-9 |
Dabrafenib mesylate is a mutant-BRAF kinase inhibitor.... |
| Dabrafenib Mesylate |
1195768-06-9 |
Dabrafenib mesylate is a mutant-BRAF kinase inhibitor.... |
| Dabrafenib Mesylate |
1195768-06-9 |
Dabrafenib mesylate is a mutant-BRAF kinase inhibitor.... |
| Dabrafenib Mesylate |
1195768-06-9 |
Dabrafenib mesylate is a mutant-BRAF kinase inhibitor.... |
| Dabrafenib Mesylate |
1195768-06-9 |
Dabrafenib mesylate is a mutant-BRAF kinase inhibitor.... |
| Dabrafenib Mesylate |
1195768-06-9 |
Dabrafenib mesylate is a mutant-BRAF kinase inhibitor.... |
| Danusertib(PHA-739358) |
827318-97-8 |
Danusertib is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.... |
| Danusertib(PHA-739358) |
827318-97-8 |
Danusertib is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.... |
| Dapoxetine HCl |
129938-20-1 |
Dapoxetine, marketed as Priligy, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18-64 years old.... |
| Dapoxetine HCl |
129938-20-1 |
Dapoxetine, marketed as Priligy, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18-64 years old.... |
| Dapoxetine HCl |
129938-20-1 |
Dapoxetine, marketed as Priligy, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18-64 years old.... |
| Dasatinib |
302962-49-8 |
Dasatinib is a potent dual Src/Abl inhibitor.... |
| Dasatinib |
302962-49-8 |
Dasatinib is a potent dual Src/Abl inhibitor.... |
| Dovitinib Dilactic acid (TKI258 Dilactic acid) |
852433-84-2 |
Dovitinib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, VEGFR2, VEGFR3, platelet-derived growth factor receptor (PDGFR) β, and fibroblast growth factor growth (FGFR)1, FGFR2, and FGFR3 (fibroblast growth factor receptors 1, 2, and 3).... |
| Dovitinib Dilactic acid (TKI258 Dilactic acid) |
852433-84-2 |
Dovitinib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, VEGFR2, VEGFR3, platelet-derived growth factor receptor (PDGFR) β, and fibroblast growth factor growth (FGFR)1, FGFR2, and FGFR3 (fibroblast growth factor receptors 1, 2, and 3).... |
| Dovitinib Dilactic acid (TKI258 Dilactic acid) |
852433-84-2 |
Dovitinib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, VEGFR2, VEGFR3, platelet-derived growth factor receptor (PDGFR) β, and fibroblast growth factor growth (FGFR)1, FGFR2, and FGFR3 (fibroblast growth factor receptors 1, 2, and 3).... |
| E-3810 |
117976-90-6 |
E-3810 is a novel dual inhibitor of the VEGF and FGF receptors.... |
| E-7050 |
928037-13-2 |
E-7050 is novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases.... |
| E-7050 |
928037-13-2 |
E-7050 is novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases.... |
| E-7050 |
928037-13-2 |
E-7050 is novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases.... |
| E-7050 |
928037-13-2 |
E-7050 is novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases.... |
| E-7050 |
928037-13-2 |
E-7050 is novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases.... |
| E7080 (Lenvatinib) |
417716-92-8 |
E7080 is an orally active inhibitor of multiple receptor tyrosine kinases, mostly for VEGFR2 (KDR)/VEGFR3 (Flt-4).... |
| Elacridar HCl |
143851-98-3 |
Elacridar HCl is a specific P-glycoprotein (P-gp) inhibitor.... |
| Elacridar HCl |
143851-98-3 |
Elacridar HCl is a specific P-glycoprotein (P-gp) inhibitor.... |
| Elacridar HCl |
143851-98-3 |
Elacridar HCl is a specific P-glycoprotein (P-gp) inhibitor.... |
| EMD-1214063 |
1100598-32-0 |
EMD-1214063 is a potent and selective inhibitor of c-Met.... |
| EMD-1214063 |
1100598-32-0 |
EMD-1214063 is a potent and selective inhibitor of c-Met.... |
| EMD-1214063 |
1100598-32-0 |
EMD-1214063 is a potent and selective inhibitor of c-Met.... |
| EMD-1214063 |
1100598-32-0 |
EMD-1214063 is a potent and selective inhibitor of c-Met.... |
| EMD-1214063 |
1100598-32-0 |
EMD-1214063 is a potent and selective inhibitor of c-Met.... |
| EMD-1214063 |
1100598-32-0 |
EMD-1214063 is a potent and selective inhibitor of c-Met.... |
| EMD-1214063 |
1100598-32-0 |
EMD-1214063 is a potent and selective inhibitor of c-Met.... |
| Empagliflozin |
864070-44-0 |
.... |
| ENMD-2076 |
1291074-87-7 |
ENMD-2076 is a potent inhibitor of Aurora A and Aurora B with IC50s of 14 and 350 nM, respectively.... |
| ENMD-2076 |
1291074-87-7 |
ENMD-2076 is a potent inhibitor of Aurora A and Aurora B with IC50s of 14 and 350 nM, respectively.... |
| ENMD-2076 |
1291074-87-7 |
ENMD-2076 is a potent inhibitor of Aurora A and Aurora B with IC50s of 14 and 350 nM, respectively.... |
| ENMD-2076 |
1291074-87-7 |
ENMD-2076 is a potent inhibitor of Aurora A and Aurora B with IC50s of 14 and 350 nM, respectively.... |
| EPZ004777 |
1338466-77-5 |
.... |
| EPZ004777 |
1338466-77-5 |
.... |
| Erlotinib Hydrochloride |
183319-69-9 |
Erlotinib is a selective, orally available small-molecule inhibitor of the HER1/EGFR tyrosine kinase domain, used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.... |
| Erlotinib Hydrochloride |
183319-69-9 |
Erlotinib is a selective, orally available small-molecule inhibitor of the HER1/EGFR tyrosine kinase domain, used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.... |
| Fasudil hydrochloride |
105628-07-7 |
.... |
| Fasudil hydrochloride |
105628-07-7 |
.... |
| FLLL32 |
1226895-15-3 |
FLLL32 is a novel and small molecule inhibitor of the STAT3 pathway.... |
| FLLL32 |
1226895-15-3 |
FLLL32 is a novel and small molecule inhibitor of the STAT3 pathway.... |
| FLLL32 |
1226895-15-3 |
FLLL32 is a novel and small molecule inhibitor of the STAT3 pathway.... |
| FLLL32 |
1226895-15-3 |
FLLL32 is a novel and small molecule inhibitor of the STAT3 pathway.... |
| FLLL32 |
1226895-15-3 |
FLLL32 is a novel and small molecule inhibitor of the STAT3 pathway.... |
| FLLL32 |
1226895-15-3 |
FLLL32 is a novel and small molecule inhibitor of the STAT3 pathway.... |
| Gefitinib |
184475-35-2 |
Gefitinib, a synthetic anilinoquinazoline, directly and specificly inhibits tyrosine kinase (TK) phosphorylation on the epidermal growth factor receptor (EGFR) by competing for the ATP-binding site, which leads to suppression of the EGFR pathway (HER-kinase axis).... |
| Gefitinib |
184475-35-2 |
Gefitinib, a synthetic anilinoquinazoline, directly and specificly inhibits tyrosine kinase (TK) phosphorylation on the epidermal growth factor receptor (EGFR) by competing for the ATP-binding site, which leads to suppression of the EGFR pathway (HER-kinase axis).... |
| GSK1070916 |
942918-07-2 |
GSK1070916 is a novel, potent and selective ATP competitive inhibitor of Aurora B and Aurora C kinases with IC50 values of 3.5 and 6.5 nM, respectively.... |
| GSK1070916 |
942918-07-2 |
GSK1070916 is a novel, potent and selective ATP competitive inhibitor of Aurora B and Aurora C kinases with IC50 values of 3.5 and 6.5 nM, respectively.... |
| GSK1070916 |
942918-07-2 |
GSK1070916 is a novel, potent and selective ATP competitive inhibitor of Aurora B and Aurora C kinases with IC50 values of 3.5 and 6.5 nM, respectively.... |
| GSK1070916 |
942918-07-2 |
GSK1070916 is a novel, potent and selective ATP competitive inhibitor of Aurora B and Aurora C kinases with IC50 values of 3.5 and 6.5 nM, respectively.... |
| GSK1349572 |
1051375-16-6 |
.... |
| GSK1349572 |
1051375-16-6 |
.... |
| GSK1349572 |
1051375-16-6 |
.... |
| GSK1349572 |
1051375-16-6 |
.... |
| GSK1838705A |
1116235-97-2 |
GSK1838705A is a small-molecule IGF-IR and the insulin receptor inhibitor.... |
| GSK1838705A |
1116235-97-2 |
GSK1838705A is a small-molecule IGF-IR and the insulin receptor inhibitor.... |
| GSK1838705A |
1116235-97-2 |
GSK1838705A is a small-molecule IGF-IR and the insulin receptor inhibitor.... |
| GSK1838705A |
1116235-97-2 |
GSK1838705A is a small-molecule IGF-IR and the insulin receptor inhibitor.... |
| Gsk1904529A |
1089283-49-7 |
GSK1904529A is a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.... |
| Gsk1904529A |
1089283-49-7 |
GSK1904529A is a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.... |
| Gsk1904529A |
1089283-49-7 |
GSK1904529A is a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.... |
| GSK256066 |
801312-28-7 |
.... |
| GW 441756 |
504433-23-2 |
GW441756 is a potent and selective inhibitor of the NGF receptor tyrosine kinase A (TrkA).... |
| GW2580 |
870483-87-7 |
.... |
| Hesperadin |
422513-13-1 |
Hesperadin is an indolinone inhibitor of human Aurora B with an IC50 of 250 nM.... |
| Hesperadin |
422513-13-1 |
Hesperadin is an indolinone inhibitor of human Aurora B with an IC50 of 250 nM.... |
| Hesperadin |
422513-13-1 |
Hesperadin is an indolinone inhibitor of human Aurora B with an IC50 of 250 nM.... |
| Hesperadin |
422513-13-1 |
Hesperadin is an indolinone inhibitor of human Aurora B with an IC50 of 250 nM.... |
| IEM1754 dihydrobromide |
162831-31-4 |
.... |
| Imatinib |
152459-95-5 |
Imatinib is a 2-phenylaminopyrimidine derivative that functions as a multi-target inhibitor of tyrosine kinase enzymes with IC50 values of 0.6, 0.1 and 0.1 μM for v-Abl, c-kit and PDGFR, respectively.... |
| Imatinib |
152459-95-5 |
Imatinib is a 2-phenylaminopyrimidine derivative that functions as a multi-target inhibitor of tyrosine kinase enzymes with IC50 values of 0.6, 0.1 and 0.1 μM for v-Abl, c-kit and PDGFR, respectively.... |
| Imatinib Mesylate |
220127-57-1 |
.... |
| Imatinib Mesylate |
220127-57-1 |
.... |
| INCB018424 |
941678-49-5 |
INCB018424 is a potent and selective inhibitor of JAK1 (Janus kinase) and JAK2 with IC50 of 3.3 and 2.8 nM, respectively.... |
| INCB018424 |
941678-49-5 |
INCB018424 is a potent and selective inhibitor of JAK1 (Janus kinase) and JAK2 with IC50 of 3.3 and 2.8 nM, respectively.... |
| INCB018424 |
941678-49-5 |
INCB018424 is a potent and selective inhibitor of JAK1 (Janus kinase) and JAK2 with IC50 of 3.3 and 2.8 nM, respectively.... |
| INCB018424 |
941678-49-5 |
INCB018424 is a potent and selective inhibitor of JAK1 (Janus kinase) and JAK2 with IC50 of 3.3 and 2.8 nM, respectively.... |
| INCB28060 |
1029712-80-8 |
INCB28060 is a novel inhibitor of c-MET kinase.... |
| INCB28060 |
1029712-80-8 |
INCB28060 is a novel inhibitor of c-MET kinase.... |
| Ispinesib |
336113-53-2 |
Ispinesib is a potent allosteric small-molecule inhibitor of kinesin spindle protein (KSP, also known as HsEg5).... |
| Ispinesib |
336113-53-2 |
Ispinesib is a potent allosteric small-molecule inhibitor of kinesin spindle protein (KSP, also known as HsEg5).... |
| Ispinesib |
336113-53-2 |
Ispinesib is a potent allosteric small-molecule inhibitor of kinesin spindle protein (KSP, also known as HsEg5).... |
| JNJ-38877605 |
943540-75-8 |
JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met.... |
| JNJ-38877605 |
943540-75-8 |
JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met.... |
| JNJ-38877605 |
943540-75-8 |
JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met.... |
| JNJ-38877605 |
943540-75-8 |
JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met.... |
| JNJ-38877605 |
943540-75-8 |
JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met.... |
| KRN 633 |
286370-15-8 |
KRN 633 is a novel quinazoline urea derivative and a potent ATP-competitive inhibitor of VEGFR-1, -2 and -3 with IC50s of 170, 160, and 125 nM, respectively.... |
| Lapatinib |
231277-92-2 |
Lapatinib is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases with IC50 of 10.2 and 9.8 nM, respectively.... |
| Lapatinib |
231277-92-2 |
Lapatinib is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases with IC50 of 10.2 and 9.8 nM, respectively.... |
| LDK378 |
1032900-25-6 |
.... |
| LDK378 |
1032900-25-6 |
.... |
| Lestaurtinib |
111358-88-4 |
Lestaurtinib is a potent and orally available fms-like kinase (FLT3) inhibitor.... |
| Lestaurtinib |
111358-88-4 |
Lestaurtinib is a potent and orally available fms-like kinase (FLT3) inhibitor.... |
| Linifanib |
796967-16-3 |
Linifanib is a receptor tyrosine kinase (RTK) inhibitor.... |
| Linifanib |
796967-16-3 |
Linifanib is a receptor tyrosine kinase (RTK) inhibitor.... |
| Linifanib |
796967-16-3 |
Linifanib is a receptor tyrosine kinase (RTK) inhibitor.... |
| Linifanib |
796967-16-3 |
Linifanib is a receptor tyrosine kinase (RTK) inhibitor.... |
| LY2784544 |
1229236-86-5 |
LY2784544 has been identified as being highly selective for JAK 2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.... |
| LY2784544 |
1229236-86-5 |
LY2784544 has been identified as being highly selective for JAK 2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.... |
| LY2784544 |
1229236-86-5 |
LY2784544 has been identified as being highly selective for JAK 2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.... |
| LY2784544 |
1229236-86-5 |
LY2784544 has been identified as being highly selective for JAK 2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.... |
| LY2801653 |
1206799-15-6 |
LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase.... |
| LY2811376 |
1194044-20-6 |
.... |
| LY2811376 |
1194044-20-6 |
.... |
| LY2811376 |
1194044-20-6 |
.... |
| LY2811376 |
1194044-20-6 |
.... |
| LY335979 |
167465-36-3 |
LY335979 is a novel potent modulator of P-glycoprotein (Pgp).... |
| LY335979 |
167465-36-3 |
LY335979 is a novel potent modulator of P-glycoprotein (Pgp).... |
| LY335979 |
167465-36-3 |
LY335979 is a novel potent modulator of P-glycoprotein (Pgp).... |
| Masitinib |
790299-79-5 |
Masitinib is a potent and selective inhibitor of KIT.... |
| Masitinib |
790299-79-5 |
Masitinib is a potent and selective inhibitor of KIT.... |
| Masitinib |
790299-79-5 |
Masitinib is a potent and selective inhibitor of KIT.... |
| MK-2461 |
917879-39-1 |
.... |
| MK-5108 |
1010085-13-8 |
MK-5108 is a potent and selective Aurora A inhibitor with IC50 of 0.064 nM.... |
| MK-5108 |
1010085-13-8 |
MK-5108 is a potent and selective Aurora A inhibitor with IC50 of 0.064 nM.... |
| MK-5108 |
1010085-13-8 |
MK-5108 is a potent and selective Aurora A inhibitor with IC50 of 0.064 nM.... |
| MK-5108 |
1010085-13-8 |
MK-5108 is a potent and selective Aurora A inhibitor with IC50 of 0.064 nM.... |
| MK-8033 |
1196681-38-5 |
MK-8033 is a dual c-Met/Ron inhibitor.... |
| MK-8033 |
1196681-38-5 |
MK-8033 is a dual c-Met/Ron inhibitor.... |
| MK-8033 |
1196681-38-5 |
MK-8033 is a dual c-Met/Ron inhibitor.... |
| MK-8033 |
1196681-38-5 |
MK-8033 is a dual c-Met/Ron inhibitor.... |
| MK-8033 |
1196681-38-5 |
MK-8033 is a dual c-Met/Ron inhibitor.... |
| MK3207 HCl |
957116-20-0 |
.... |
| MK3207 HCl |
957116-20-0 |
.... |
| MK3207 HCl |
957116-20-0 |
.... |
| MK3207 HCl |
957116-20-0 |
.... |
| MK8745 |
885325-71-3 |
.... |
| MLN8054 |
869363-13-3 |
MLN8054 is a potent Aurora A inhibitor with an IC50 of 4 nM.... |
| MLN8054 |
869363-13-3 |
MLN8054 is a potent Aurora A inhibitor with an IC50 of 4 nM.... |
| MLN8054 |
869363-13-3 |
MLN8054 is a potent Aurora A inhibitor with an IC50 of 4 nM.... |
| MLN8054 |
869363-13-3 |
MLN8054 is a potent Aurora A inhibitor with an IC50 of 4 nM.... |
| MLN8237 |
1028486-01-2 |
MLN8237 is a selective Aurora A and Aurora B inhibitor with IC50 values of 1.2 and 396.5 nM, respectively.... |
| MLN8237 |
1028486-01-2 |
MLN8237 is a selective Aurora A and Aurora B inhibitor with IC50 values of 1.2 and 396.5 nM, respectively.... |
| MLN8237 |
1028486-01-2 |
MLN8237 is a selective Aurora A and Aurora B inhibitor with IC50 values of 1.2 and 396.5 nM, respectively.... |
| MLN8237 |
1028486-01-2 |
MLN8237 is a selective Aurora A and Aurora B inhibitor with IC50 values of 1.2 and 396.5 nM, respectively.... |
| Motesanib Diphosphate |
453562-69-1 |
.... |
| Mozavaptan |
137975-06-5 |
.... |
| MP-470 |
850879-09-03 |
MP-470 is a novel orally bioavailable mutitargeting tyrosine kinase inhibitor with activity against mutant c-KIT, PDGFRa and FLT3.... |
| MP-470 |
850879-09-03 |
MP-470 is a novel orally bioavailable mutitargeting tyrosine kinase inhibitor with activity against mutant c-KIT, PDGFRa and FLT3.... |
| MP-470 |
850879-09-03 |
MP-470 is a novel orally bioavailable mutitargeting tyrosine kinase inhibitor with activity against mutant c-KIT, PDGFRa and FLT3.... |
| MP-470 |
850879-09-03 |
MP-470 is a novel orally bioavailable mutitargeting tyrosine kinase inhibitor with activity against mutant c-KIT, PDGFRa and FLT3.... |
| Nelarabine |
121032-29-9 |
.... |
| Nelarabine |
121032-29-9 |
.... |
| Nelarabine |
121032-29-9 |
.... |
| Nelarabine |
121032-29-9 |
.... |
| Neratinib |
698387-09-6 |
Neratinib is a dual inhibitor of the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) kinases.... |
| Neratinib |
698387-09-6 |
Neratinib is a dual inhibitor of the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) kinases.... |
| Neratinib |
698387-09-6 |
Neratinib is a dual inhibitor of the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) kinases.... |
| Nilotinib |
641571-10-0 |
Nilotinib inhibits the kinases BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11 and ZAK.... |
| Nilotinib |
641571-10-0 |
Nilotinib inhibits the kinases BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11 and ZAK.... |
| Nilotinib |
641571-10-0 |
Nilotinib inhibits the kinases BCR-ABL, KIT, LCK, EPHA3, EPHA8, DDR1, DDR2, PDGFRB, MAPK11 and ZAK.... |
| Noopept |
157115-85-0 |
Noopept (GVS-111) is a medication promoted and prescribed in Russia and neighbouring countries as a nootropic.... |
| NSC 87877 |
56990-57-9 |
NSC 87877 is a potent inhibitor of shp2 and shp1 protein tyrosine phosphatases (PTP).... |
| NUTLIN 3 |
548472-68-0 |
.... |
| NUTLIN 3 |
548472-68-0 |
.... |
| NVP-ADW742 |
475488-23-4 |
NVP-ADW742 is a small molecule ATP-competitive inhibitor of the IGF-I receptor (IGF-IR) with an IC50 of 0.17 µM.... |
| NVP-AEW541 |
475489-16-8 |
NVP-AEW541 is a novel, potent, and selective inhibitor of the IGF-IR kinase.... |
| NVP-AEW541 |
475489-16-8 |
NVP-AEW541 is a novel, potent, and selective inhibitor of the IGF-IR kinase.... |
| NVP-AEW541 |
475489-16-8 |
NVP-AEW541 is a novel, potent, and selective inhibitor of the IGF-IR kinase.... |
| NVP-AEW541 |
475489-16-8 |
NVP-AEW541 is a novel, potent, and selective inhibitor of the IGF-IR kinase.... |
| NVP-BHG712 |
940310-85-0 |
.... |
| NVP-BHG712 |
940310-85-0 |
.... |
| NVP-BHG712 |
940310-85-0 |
.... |
| NVP-BHG712 |
940310-85-0 |
.... |
| NVP-BSK805 dihydrochloride |
1092499-93-8 |
NVP-BSK805 can potently suppress JAK2 with IC50 of 0.5 nM, and displays more than 20-fold selectivity towards JAK1, JAK3, and TYK2.... |
| NVP-BSK805 dihydrochloride |
1092499-93-8 |
NVP-BSK805 can potently suppress JAK2 with IC50 of 0.5 nM, and displays more than 20-fold selectivity towards JAK1, JAK3, and TYK2.... |
| NVP-BSK805 dihydrochloride |
1092499-93-8 |
NVP-BSK805 can potently suppress JAK2 with IC50 of 0.5 nM, and displays more than 20-fold selectivity towards JAK1, JAK3, and TYK2.... |
| NVP-BSK805 dihydrochloride |
1092499-93-8 |
NVP-BSK805 can potently suppress JAK2 with IC50 of 0.5 nM, and displays more than 20-fold selectivity towards JAK1, JAK3, and TYK2.... |
| NVP-BVU972 |
1185763-69-2 |
NVP-BVU972 is a selective and potent MET kinase inhibitor with IC50 of 14 nM.... |
| NVP-BVU972 |
1185763-69-2 |
NVP-BVU972 is a selective and potent MET kinase inhibitor with IC50 of 14 nM.... |
| NVP-BVU972 |
1185763-69-2 |
NVP-BVU972 is a selective and potent MET kinase inhibitor with IC50 of 14 nM.... |
| NVP-BVU972 |
1185763-69-2 |
NVP-BVU972 is a selective and potent MET kinase inhibitor with IC50 of 14 nM.... |
| Org 27569 |
868273-06-7 |
.... |
| Osi-906 |
867160-71-2 |
Osi-906 is a selective and orally efficacious dual inhibitor of the IGF-1 (insulin-like growth factor 1) receptor and insulin receptor (IR).... |
| Osi-906 |
867160-71-2 |
Osi-906 is a selective and orally efficacious dual inhibitor of the IGF-1 (insulin-like growth factor 1) receptor and insulin receptor (IR).... |
| Osi-906 |
867160-71-2 |
Osi-906 is a selective and orally efficacious dual inhibitor of the IGF-1 (insulin-like growth factor 1) receptor and insulin receptor (IR).... |
| Osi-906 |
867160-71-2 |
Osi-906 is a selective and orally efficacious dual inhibitor of the IGF-1 (insulin-like growth factor 1) receptor and insulin receptor (IR).... |
| OSI930 |
728033-96-3 |
.... |
| OSI930 |
728033-96-3 |
.... |
| OSI930 |
728033-96-3 |
.... |
| p53 and MDM2 proteins-interaction-inhibitor chiral |
939981-37-0 |
.... |
| Pacritinib |
937272-79-2 |
Pacritinib is a novel oral JAK2 inhibitor.... |
| Pazopanib |
444731-52-6 |
Pazopanib is a novel orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor (VEGFR) -1, -2, -3, PDGFR-α, PDGFR-β, and c-Kit with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.... |
| Pazopanib |
444731-52-6 |
Pazopanib is a novel orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor (VEGFR) -1, -2, -3, PDGFR-α, PDGFR-β, and c-Kit with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.... |
| PCI-32765(ibrutinib) |
936563-96-1 |
PCI-32765 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| PCI-32765(ibrutinib) |
936563-96-1 |
PCI-32765 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| PCI-32765(ibrutinib) |
936563-96-1 |
PCI-32765 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| PCI-32765(ibrutinib) |
936563-96-1 |
PCI-32765 is a selective and covalent inhibitor of Bruton's tyrosine kinase (Btk).... |
| PD153035 |
183322-45-4 |
PD153035 is a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase.... |
| PD153035 |
183322-45-4 |
PD153035 is a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase.... |
| PD153035 |
183322-45-4 |
PD153035 is a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase.... |
| PD168393 |
194423-15-9 |
.... |
| PD173074 |
219580-11-7 |
PD173074 is an ATP pocket inhibitor that inhibits the tyrosine kinase activities of the FGF and VEGF receptors.... |
| PD173074 |
219580-11-7 |
PD173074 is an ATP pocket inhibitor that inhibits the tyrosine kinase activities of the FGF and VEGF receptors.... |
| PD173074 |
219580-11-7 |
PD173074 is an ATP pocket inhibitor that inhibits the tyrosine kinase activities of the FGF and VEGF receptors.... |
| PD173955 |
260415-63-2 |
PD173955 is a Src family-specific tyrosine kinase inhibitor.... |
| PF-03814735 |
942487-16-3 |
.... |
| PF-04217903 |
956905-27-4 |
PF-04217903 is a novel ATP-competitive small-molecule inhibitor of c-Met kinase.... |
| PF-04217903 |
956905-27-4 |
PF-04217903 is a novel ATP-competitive small-molecule inhibitor of c-Met kinase.... |
| PF-04217903 |
956905-27-4 |
PF-04217903 is a novel ATP-competitive small-molecule inhibitor of c-Met kinase.... |
| PF-04217903 |
956905-27-4 |
PF-04217903 is a novel ATP-competitive small-molecule inhibitor of c-Met kinase.... |
| PF06465469 |
1407966-77-1 |
PF-06465469 is a potent inhibitor of interleukin-2 inducible T cell kinase (ITK).... |
| PF06465469 |
1407966-77-1 |
PF-06465469 is a potent inhibitor of interleukin-2 inducible T cell kinase (ITK).... |
| PF299804 |
1110813-31-4 |
PF299804 is an irreversible Pan-ERBB inhibitor.... |
| PF299804 |
1110813-31-4 |
PF299804 is an irreversible Pan-ERBB inhibitor.... |
| PF299804 |
1110813-31-4 |
PF299804 is an irreversible Pan-ERBB inhibitor.... |
| PF299804 |
1110813-31-4 |
PF299804 is an irreversible Pan-ERBB inhibitor.... |
| PF573228 |
869288-64-2 |
.... |
| PHA-665752 |
477575-56-7 |
PHA-665752 is a potent, ATP-competitive inhibitor of c-Met kinase with an IC50 of 9 nM and Ki value of 4 nM.... |
| PHA-665752 |
477575-56-7 |
PHA-665752 is a potent, ATP-competitive inhibitor of c-Met kinase with an IC50 of 9 nM and Ki value of 4 nM.... |
| PHA-665752 |
477575-56-7 |
PHA-665752 is a potent, ATP-competitive inhibitor of c-Met kinase with an IC50 of 9 nM and Ki value of 4 nM.... |
| PHA-665752 |
477575-56-7 |
PHA-665752 is a potent, ATP-competitive inhibitor of c-Met kinase with an IC50 of 9 nM and Ki value of 4 nM.... |
| PKC412(midostaurin) |
120685-11-2 |
PKC412 is a selective protein kinase C (PKC) inhibitor.... |
| Plerixafor 8HCl |
155148-31-5 |
.... |
| PP121 |
1092788-83-4 |
.... |
| PP121 |
1092788-83-4 |
.... |
| PQ 401 |
196868-63-0 |
.... |
| PRT062607 (P505-15, BIIB057) HCl |
1370261-97-4,1370261-96-3(free base) |
PRT062607 is a novel, highly selective, and orally bioavailable small molecule spleen tyrosine kinase (SYK) inhibitor with an IC50 of 1 nM.... |
| PRT062607 (P505-15, BIIB057) HCl |
1370261-97-4,1370261-96-3(free base) |
PRT062607 is a novel, highly selective, and orally bioavailable small molecule spleen tyrosine kinase (SYK) inhibitor with an IC50 of 1 nM.... |
| R406 |
841290-81-1 |
R406 is an ATP-competitive inhibitor of spleen tyrosine kinase (Syk) kinase with an IC50 of 41 nM.... |
| R406 |
841290-81-1 |
R406 is an ATP-competitive inhibitor of spleen tyrosine kinase (Syk) kinase with an IC50 of 41 nM.... |
| R406 |
841290-81-1 |
R406 is an ATP-competitive inhibitor of spleen tyrosine kinase (Syk) kinase with an IC50 of 41 nM.... |
| R406 |
841290-81-1 |
R406 is an ATP-competitive inhibitor of spleen tyrosine kinase (Syk) kinase with an IC50 of 41 nM.... |
| R406 |
841290-81-1 |
R406 is an ATP-competitive inhibitor of spleen tyrosine kinase (Syk) kinase with an IC50 of 41 nM.... |
| R935788 |
1025687-58-4 |
R935788 is a potent spleen tyrosine kinase inhibitor.... |
| R935788 |
1025687-58-4 |
R935788 is a potent spleen tyrosine kinase inhibitor.... |
| RAF265 |
927880-90-8 |
RAF265 is a selective and potent inhibitor of RAF and VEGFR2.... |
| RAF265 |
927880-90-8 |
RAF265 is a selective and potent inhibitor of RAF and VEGFR2.... |
| RAF265 |
927880-90-8 |
RAF265 is a selective and potent inhibitor of RAF and VEGFR2.... |
| RAF265 |
927880-90-8 |
RAF265 is a selective and potent inhibitor of RAF and VEGFR2.... |
| Regorafenib |
755037-03-7 |
Regorafenib is an oral multi-kinase inhibitor.... |
| Regorafenib |
755037-03-7 |
Regorafenib is an oral multi-kinase inhibitor.... |
| Regorafenib |
755037-03-7 |
Regorafenib is an oral multi-kinase inhibitor.... |
| Regorafenib |
755037-03-7 |
Regorafenib is an oral multi-kinase inhibitor.... |
| RN486 |
1242156-23-5 |
RN486 is a potent, selectively and proprietary Bruton's tyrosine kinase (Btk) inhibitor.... |
| RN486 |
1242156-23-5 |
RN486 is a potent, selectively and proprietary Bruton's tyrosine kinase (Btk) inhibitor.... |
| RN486 |
1242156-23-5 |
RN486 is a potent, selectively and proprietary Bruton's tyrosine kinase (Btk) inhibitor.... |
| Roflumilast |
162401-32-3 |
.... |
| Roflumilast |
162401-32-3 |
.... |
| Saracatinib |
379231-04-6 |
Saracatinib is a novel Src family kinase/Abl dual-kinase inhibitor for c-Src and v-Abl with IC50 values of 2.7 and 30 nM, respectively.... |
| Saracatinib |
379231-04-6 |
Saracatinib is a novel Src family kinase/Abl dual-kinase inhibitor for c-Src and v-Abl with IC50 values of 2.7 and 30 nM, respectively.... |
| Saracatinib |
379231-04-6 |
Saracatinib is a novel Src family kinase/Abl dual-kinase inhibitor for c-Src and v-Abl with IC50 values of 2.7 and 30 nM, respectively.... |
| SB 431542 |
301836-41-9 |
SB-431542 is a novel, small molecule ATP-mimetic inhibitor of the kinase activity associated with members of the activin receptor-like kinase (ALK) family-specifically ALK5 (TGF- β type I receptor, TGF- β RI), ALK4 (activin type I receptor), and ALK7 (nodal type I receptor).... |
| SB 431542 |
301836-41-9 |
SB-431542 is a novel, small molecule ATP-mimetic inhibitor of the kinase activity associated with members of the activin receptor-like kinase (ALK) family-specifically ALK5 (TGF- β type I receptor, TGF- β RI), ALK4 (activin type I receptor), and ALK7 (nodal type I receptor).... |
| SB 431542 |
301836-41-9 |
SB-431542 is a novel, small molecule ATP-mimetic inhibitor of the kinase activity associated with members of the activin receptor-like kinase (ALK) family-specifically ALK5 (TGF- β type I receptor, TGF- β RI), ALK4 (activin type I receptor), and ALK7 (nodal type I receptor).... |
| SB 525334 |
356559-20-1 |
SB525334 is a potent and selective inhibitor of the transforming growth factor-β1 (TGF-β1) receptor (ALK5).... |
| SB408124 |
288150-92-5 |
.... |
| SB408124 |
288150-92-5 |
.... |
| SB408124 |
288150-92-5 |
.... |
| SB408124 |
288150-92-5 |
.... |
| SB743921 |
940929-33-9 |
SB743921 is a second generation kinesin spindle protein (KSP) inhibitor.... |
| SB743921 |
940929-33-9 |
SB743921 is a second generation kinesin spindle protein (KSP) inhibitor.... |
| SB743921 |
940929-33-9 |
SB743921 is a second generation kinesin spindle protein (KSP) inhibitor.... |
| SB743921 |
940929-33-9 |
SB743921 is a second generation kinesin spindle protein (KSP) inhibitor.... |
| SB743921 |
940929-33-9 |
SB743921 is a second generation kinesin spindle protein (KSP) inhibitor.... |
| SB743921 |
940929-33-9 |
SB743921 is a second generation kinesin spindle protein (KSP) inhibitor.... |
| SCH727965 |
779353-01-4 |
.... |
| SCH727965 |
779353-01-4 |
.... |
| SCH727965 |
779353-01-4 |
.... |
| SGX-523 |
1022150-57-7 |
SGX-523 is a potent and selective Met inhibitor with an IC50 of 4 nM.... |
| SGX-523 |
1022150-57-7 |
SGX-523 is a potent and selective Met inhibitor with an IC50 of 4 nM.... |
| SGX-523 |
1022150-57-7 |
SGX-523 is a potent and selective Met inhibitor with an IC50 of 4 nM.... |
| SGX-523 |
1022150-57-7 |
SGX-523 is a potent and selective Met inhibitor with an IC50 of 4 nM.... |
| SKLB1002 |
1225451-84-2 |
.... |
| SNS-314 |
1057249-41-8 |
SNS-314 is a potent and selective Aurora kinase inhibitor.... |
| Sorafenib |
284461-73-0 |
Sorafenib is a small molecular inhibitor of several tyrosine protein kinases including VEGFR (vascular endothelial growth factor receptors) and PDGFR (platelet-derived growth factor receptors) and Raf kinases.... |
| Sorafenib |
284461-73-0 |
Sorafenib is a small molecular inhibitor of several tyrosine protein kinases including VEGFR (vascular endothelial growth factor receptors) and PDGFR (platelet-derived growth factor receptors) and Raf kinases.... |
| Sorafenib |
284461-73-0 |
Sorafenib is a small molecular inhibitor of several tyrosine protein kinases including VEGFR (vascular endothelial growth factor receptors) and PDGFR (platelet-derived growth factor receptors) and Raf kinases.... |
| Sorafenib |
284461-73-0 |
Sorafenib is a small molecular inhibitor of several tyrosine protein kinases including VEGFR (vascular endothelial growth factor receptors) and PDGFR (platelet-derived growth factor receptors) and Raf kinases.... |
| SU 5402 |
215543-92-3 |
SU5402 is a potent and selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR).... |
| Su11274 |
658084-23-2 |
Su11274 is a ATP-competitive c-Met specific inhibitor.... |
| Su11274 |
658084-23-2 |
Su11274 is a ATP-competitive c-Met specific inhibitor.... |
| Su11274 |
658084-23-2 |
Su11274 is a ATP-competitive c-Met specific inhibitor.... |
| Su11274 |
658084-23-2 |
Su11274 is a ATP-competitive c-Met specific inhibitor.... |
| SU14813 |
627908-92-3 |
SU14813 is a novel multiple receptor tyrosine kinase inhibitor.... |
| SU14813 |
627908-92-3 |
SU14813 is a novel multiple receptor tyrosine kinase inhibitor.... |
| SU14813 |
627908-92-3 |
SU14813 is a novel multiple receptor tyrosine kinase inhibitor.... |
| SU14813 |
627908-92-3 |
SU14813 is a novel multiple receptor tyrosine kinase inhibitor.... |
| SU5416 |
204005-46-9 |
.... |
| Sunitinib |
557795-19-4 |
Sunitinib is a multitargeted kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR) -1, 2 and 3, platelet-derived growth factor receptors (PDGFR)-α and β, Flt3 (Fms-like tyrosyl kinase-3), Ret, and Kit.... |
| Sunitinib |
557795-19-4 |
Sunitinib is a multitargeted kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR) -1, 2 and 3, platelet-derived growth factor receptors (PDGFR)-α and β, Flt3 (Fms-like tyrosyl kinase-3), Ret, and Kit.... |
| Sunitinib |
557795-19-4 |
Sunitinib is a multitargeted kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR) -1, 2 and 3, platelet-derived growth factor receptors (PDGFR)-α and β, Flt3 (Fms-like tyrosyl kinase-3), Ret, and Kit.... |
| TAE684 |
761439-42-3 |
TAE684 is a potent ALK inhibitor with an IC50 of 3 nM.... |
| TAE684 |
761439-42-3 |
TAE684 is a potent ALK inhibitor with an IC50 of 3 nM.... |
| TAE684 |
761439-42-3 |
TAE684 is a potent ALK inhibitor with an IC50 of 3 nM.... |
| TAE684 |
761439-42-3 |
TAE684 is a potent ALK inhibitor with an IC50 of 3 nM.... |
| TAK901 |
934541-31-8 |
.... |
| TAK901 |
934541-31-8 |
.... |
| TAK901 |
934541-31-8 |
.... |
| TAK901 |
934541-31-8 |
.... |
| tariquidar |
206873-63-4 |
.... |
| TCS 401 |
243967-42-2 |
TCS 401 is a selective inhibitor of protein-tyrosine phosphatase 1B (PTP1B) with a Ki value of 290 nM.... |
| Telmisartan |
144701-48-4 |
Telmisartan is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the treatment of hypertension.... |
| TG101209 |
936091-14-4 |
TG101209 potently inhibits JAK2, FLT3 and RET kinases with IC50 values of 6, 25 and 17 nM, respectively.... |
| TG101209 |
936091-14-4 |
TG101209 potently inhibits JAK2, FLT3 and RET kinases with IC50 values of 6, 25 and 17 nM, respectively.... |
| TG101209 |
936091-14-4 |
TG101209 potently inhibits JAK2, FLT3 and RET kinases with IC50 values of 6, 25 and 17 nM, respectively.... |
| TG101209 |
936091-14-4 |
TG101209 potently inhibits JAK2, FLT3 and RET kinases with IC50 values of 6, 25 and 17 nM, respectively.... |
| TG101348 |
936091-26-8 |
TG101348 is a selective small-molecule inhibitor of JAK2.... |
| TG101348 |
936091-26-8 |
TG101348 is a selective small-molecule inhibitor of JAK2.... |
| TG101348 |
936091-26-8 |
TG101348 is a selective small-molecule inhibitor of JAK2.... |
| TG101348 |
936091-26-8 |
TG101348 is a selective small-molecule inhibitor of JAK2.... |
| Tivozanib |
475108-18-0 |
Tivozanib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.... |
| Tivozanib |
475108-18-0 |
Tivozanib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.... |
| Tivozanib |
475108-18-0 |
Tivozanib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.... |
| TKI-258 |
405169-16-6 |
TKI-258 is a novel and multitargeted receptor tyrosine kinase (RTK) inhibitor.... |
| TKI-258 |
405169-16-6 |
TKI-258 is a novel and multitargeted receptor tyrosine kinase (RTK) inhibitor.... |
| TKI-258 |
405169-16-6 |
TKI-258 is a novel and multitargeted receptor tyrosine kinase (RTK) inhibitor.... |
| TKI-258 |
405169-16-6 |
TKI-258 is a novel and multitargeted receptor tyrosine kinase (RTK) inhibitor.... |
| TKI-258 |
405169-16-6 |
TKI-258 is a novel and multitargeted receptor tyrosine kinase (RTK) inhibitor.... |
| TKI-258 |
405169-16-6 |
TKI-258 is a novel and multitargeted receptor tyrosine kinase (RTK) inhibitor.... |
| TKI-258 |
405169-16-6 |
TKI-258 is a novel and multitargeted receptor tyrosine kinase (RTK) inhibitor.... |
| Tofacitinib citrate |
540737-29-9 |
Tofacitinib citrate is a PAN-JAK inhibitor with phenomenal selectivity against the human kinome.... |
| Tofacitinib citrate |
540737-29-9 |
Tofacitinib citrate is a PAN-JAK inhibitor with phenomenal selectivity against the human kinome.... |
| Torcetrapib |
262352-17-0 |
.... |
| TSU-68 (SU6668) |
252916-29-3 |
TSU-68 is an ATP-competitive and highly potent PDGFR inhibitor.... |
| TTNPB |
71441-28-6 |
.... |
| Vandetanib |
443913-73-3 |
Vandetanib is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR).... |
| Vandetanib |
443913-73-3 |
Vandetanib is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR).... |
| Varlitinib |
845272-21-1 |
Varlitinib is a reversible, ATP-competitive inhibitor with nanomolar potency in both in vitro and in cell-based assays showing strong activity against EGFR, ErbB2 and ErbB4.... |
| Varlitinib |
845272-21-1 |
Varlitinib is a reversible, ATP-competitive inhibitor with nanomolar potency in both in vitro and in cell-based assays showing strong activity against EGFR, ErbB2 and ErbB4.... |
| Vatalanib Dihydrochloride base |
212141-51-0 |
.... |
| VX-680 |
639089-54-6 |
VX-680 is a highly potent and selective small-molecule inhibitor of Aurora kinases.... |
| VX-680 |
639089-54-6 |
VX-680 is a highly potent and selective small-molecule inhibitor of Aurora kinases.... |
| VX-680 |
639089-54-6 |
VX-680 is a highly potent and selective small-molecule inhibitor of Aurora kinases.... |
| VX745 |
209410-46-8 |
.... |
| VX745 |
209410-46-8 |
.... |
| WHI-P154 |
211555-04-3 |
WHI-P154 is a potent JAK3 and EGFR inhibitor.... |
| WHI-P154 |
211555-04-3 |
WHI-P154 is a potent JAK3 and EGFR inhibitor.... |
| WP1066 |
857064-38-1 |
WP1066 is a novel JAK2 inhibitor.... |
| WP1066 |
857064-38-1 |
WP1066 is a novel JAK2 inhibitor.... |
| WZ4002 |
1213269-23-8 |
WZ4002 is a potent EGFR inhibitor.... |
| WZ4002 |
1213269-23-8 |
WZ4002 is a potent EGFR inhibitor.... |
| WZ4002 |
1213269-23-8 |
WZ4002 is a potent EGFR inhibitor.... |
| WZ4002 |
1213269-23-8 |
WZ4002 is a potent EGFR inhibitor.... |
| WZ811 |
55778-02-4 |
WZ811 is a highly potent competitive CXCR4 antagonist with EC50 of 0.3nM.... |
| WZ811 |
55778-02-4 |
WZ811 is a highly potent competitive CXCR4 antagonist with EC50 of 0.3nM.... |
| XL-184 |
849217-68-1 |
XL184 is a potent inhibitor of RTKs, including MET, VEGFR2, and RET.... |
| XL-184 |
849217-68-1 |
XL184 is a potent inhibitor of RTKs, including MET, VEGFR2, and RET.... |
| XL-184 |
849217-68-1 |
XL184 is a potent inhibitor of RTKs, including MET, VEGFR2, and RET.... |
| XL-184 |
849217-68-1 |
XL184 is a potent inhibitor of RTKs, including MET, VEGFR2, and RET.... |
| XL184(free base) |
849217-68-1 |
.... |
| XL184(free base) |
849217-68-1 |
.... |
| XL184(free base) |
849217-68-1 |
.... |
| XL184(free base) |
849217-68-1 |
.... |
| XL647 |
651031-01-5 |
XL647 is a novel spectrum-selective, reversible and ATP competitive kinase inhibitor.... |
| XL647 |
651031-01-5 |
XL647 is a novel spectrum-selective, reversible and ATP competitive kinase inhibitor.... |
| Xl880 |
849217-64-7 |
XL880 is an ATP-competitive inhibitor of MET and VEGFR2/KDR.... |
| Xl880 |
849217-64-7 |
XL880 is an ATP-competitive inhibitor of MET and VEGFR2/KDR.... |
| Xl880 |
849217-64-7 |
XL880 is an ATP-competitive inhibitor of MET and VEGFR2/KDR.... |
| ZM-447439 |
331771-20-1 |
ZM-447439 is an Auroa selective ATP-competitive inhibitor that interferes with the spindle integrity checkpoint and chromosome segregation.... |
| ZM-447439 |
331771-20-1 |
ZM-447439 is an Auroa selective ATP-competitive inhibitor that interferes with the spindle integrity checkpoint and chromosome segregation.... |
| ZM-447439 |
331771-20-1 |
ZM-447439 is an Auroa selective ATP-competitive inhibitor that interferes with the spindle integrity checkpoint and chromosome segregation.... |
| ZM-447439 |
331771-20-1 |
ZM-447439 is an Auroa selective ATP-competitive inhibitor that interferes with the spindle integrity checkpoint and chromosome segregation.... |
| ZM306416 |
690206-97-4 |
ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM [1].... |
| ZM306416 |
690206-97-4 |
ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM [1].... |
| ZM323881HCl |
193000-39-4 |
ZM323881 inhibits VEGF-A-induced endothelial cell proliferation with IC50 of 8 nM and VEGF-R2 tyrosine phosphorylation [1].... |
| ZM323881HCl |
193001-14-8 |
ZM323881 inhibits VEGF-A-induced endothelial cell proliferation with IC50 of 8 nM and VEGF-R2 tyrosine phosphorylation [1].... |
点击图片查看原图
